Oxford BioTherapeutics To Collaborate With Seattle Genetics On ADCs
This article was originally published in The Pink Sheet Daily
Executive Summary
In tandem with Seattle Genetics, Oxford BioTherapeutics hopes to take a monoclonal antibody product for cancer into the clinic next year.
You may also be interested in...
Seattle Genetics Commits To Simultaneous Confirmatory Trials For Adcetris
FDA approves the antibody-drug conjugate for late stage Hodgkins lymphoma and systemic anaplastic large cell lymphoma Aug. 19.
GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies
Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.